Simply because people who carry the APOE e4 gene variant appear to have a bigger risk of great complications, the FDA suggests remaining tested for that gene variant before beginning treatment with lecanemab or donanemab. Mild cognitive impairment is significant to recognize as it increases anyone’s risk of creating dementia https://testingfordementianearme66655.pages10.com/a-review-of-testing-for-dementia-near-me-69746885